Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJoyce Harp, Haruka Okamoto
Estimating the term…
The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis, long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels, including stress hyperglycemia.
A method of reducing the amount and/or dosage of insulin necessary to reduce the severity of stress hyperglycemia in a patient, or for treating a patient suffering from stress hyperglycemia wherein the patient exhibits elevated levels of blood glucose caused or exacerbated by one or more stress-inducing stimulus or glucose-elevating stimulus, the method comprising administering, concomitantly with insulin, to a patient a therapeutically effective amount of a composition comprising a glucagon receptor (GCGR) antagonist, wherein the glucagon receptor antagonist is an isolated human monoclonal antibody, or an antigen binding fragment thereof, specific for the human GCGR.
Dependencies are inferred from the claim text.